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This commentary refers to 'The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation', by J. Steffel et al., Eur Heart J 2018;39:1330-1393.
We have read with great interest 'the 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation'. 1 Table 5 lists interactions with antiepileptic drugs (AEDs). Levetiracetam is according to the expert opinion contraindicated with NOAC because of potential P-gp interference. Since, it was highlighted that there is no evidence for levetiracetam to cause P-gp mediated drug-drug interaction with NOACs in humans. 2 In reply, the guidance authors argued that caution needs to be applied in order to have effective NOAC therapy. 3 We are concerned about the expert advice given, classifying levetiracetam as contraindicated due to concerns over potentially reduced plasma levels of NOACs. We are arguing against such advice for the following reasons:
(1) The rate of post-stroke epilepsy (PSE) is expected in 8% of stroke patients after 5 years. Predictors include severity of stroke, cortical involvement, and territory of middle cerebral artery involvement, 4 indicating a high proportion of patients with AF as stroke aetiology and the need of life-long oral anticoagulant and antiepileptic therapy. We strongly believe that these risks are much more clinically relevant than concerns about potential P-gp interference, which was only apparent in a mice model and was not replicated in humans. We agree with the authors that caution should be applied. Therapeutic drug monitoring for levetiracetam and NOAC levels should be sufficient to indicate if subtherapeutic NOAC therapy might increase risk for recurrent stroke of embolic cardiac aetiology.
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